Ohad Hammer's Comments Stream Stats
- 32 Comments, 0
, 0 
- Total Comment Stream rating - = 0
- Free E-Newsletters
- About Seeking Alpha
- About Us
- Contact Us
- What's New
- Readers Feedback
- Advertise With Us
- Contributors
- Contribute an Article
- Feature Your Book
- Our Contributors
- Anonymous Contributions
- Dispute an Article?
- Legal
- Terms of Use
- Privacy
- Copyright
'When There's Blood in the Streets', Buy Biotech Stocks
I am familiar with the company, but not intimately enough for having an opinion. The idea behind TNFerade is very exciting and has broad applications and the data seems pretty good in pancreatic and H&N cancers. Neverthless, I would be very hesitant in investing in the company before the update in pancreatic cancer, where nothing seems to work.
ohad
'When There's Blood in the Streets', Buy Biotech Stocks
I don't follow CYPB closely, but I think there is a lot of skepticism towards upcoming phase III results for milnacipran . Their cash position is enviable, no doubt.
Ohad
'When There's Blood in the Streets', Buy Biotech Stocks
I don't think it has a lot to do with guts, but basic common sense ( which seems to be a scarce commodity these days). History shows that people tend to exaggerate to both ways, and what we're witnessing, including today's selloff is merely a result of irrational behavior. Yes, things don't look good at the moment but in my opinion, now is the time to build positions selectively in segments and companies who can weather the storm. I think good biotech companies represent such a tremendous opportunity because their products and technology will always be in demand. Even companies who won't have a commercially available drug in the near future will be able to license drugs and technology to the pharmaceutical giants, who have deep pockets and are starved for new drugs. Remember: There is always a good market for good drugs.
I personally feel much more comfortable buying today, when all the fund managers and investors are dumping everything they have. They were the ones that accumulated all these stocks in the past year or two.
Ohad
'When There's Blood in the Streets', Buy Biotech Stocks
Licensing Deal Is Imminent for ArQule
EXEL looks great at the current price. Similar to the overall market, all bad news (cash burn) are factored in and when multiple licensing deals are signed, I see it going substantially higher. It is less risky than ARQL, no doubt, thanks to its broad portfolio, and this should be ARQL's model as well.
EXEL just got involved in another crowded "next big thing" area yesterday, Hsp90 inhibitors. In this case it is lagging behind BMS
and SNTA among others.
Ohad
Licensing Deal Is Imminent for ArQule
I Don't follow ARIA too closely.
Exelixis: A Platform Company for Oncology
It's very hard to predict anything in this kind of environment, but as you can see, after reaching the 5-6$ level, the stock looks pretty strong. I think that when EXEL begins to announce licensing deals for several of its compounds already next month, investors will realize that, under no circumstances will the company raise capital at the current price level. They will use the Deerfield facility to pay back GSK, since it will probably decide not opt-in on any of the joint compounds.
8$ is a reasonable price target for year end, imo.
Ohad
Exelixis: A Platform Company for Oncology
Micromet: Another Seal of Approval
Thirstycamel, I certainly see your point. Anything can happen with a company like MITI, but anything also includes negative events. A high profile collaboration can certainly lead to another jump in the price of the stock, but if I had to guess, they'll do a secondary very soon. They would be crazy not to...
Ohad
Micromet: Another Seal of Approval
I suggested taking money off the table because the recent climb wasn't based on anything new, fundamentally and partially because I speculate they’ll do a secondary soon, given the high stock price. I don’t believe in trading biotechs, but in this case, I did sell some MITI on Wednesday, so far an unwise move that cost me money, looking at the current pps…
I think that in many cases, investors ignore timing issues in drug development and although I expect good things from MITI down the road, the next data will be published only in the ASH annual meeting.
You mentioned the SGN-40 deal so there is one final point I want to make. SGEN got such a lucrative deal because it stroke it after the proof of concept clinical trial whereas MITI has already partnered MT103. Had MITI waited till now, they could have gotten a very nice deal.
Ohad
Genentech’s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans
Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
The EXEL piece will be published next week end. They must wait to GSK's decision in order to monetize their portoflio, but I expect several deals already this year.
Ohad
Poniard Pharmaceuticals: Platinum Rediscovered (Part II)
EXEL has so many shots on goal, with an excellent strategy of focusing on niche markets first, so the risk/reward ratio is quite compelling.
Immunogen's Wild Swings Due to Lack of Information at ASCO
www.hammerstockblog.co.../
btw, the dose was 60 micrograms per m2
Immunogen's Wild Swings Due to Lack of Information at ASCO
www.hammerstockblog.co.../
btw, the dose was 60 micrograms per m2